)
)
Company research20 Mar 2024
Companies That Had Their IPO in 1987: From Optimism to Black Monday
An overview of 1987's IPO landscape and stock market sentiment, as conditions turned from unabridged optimism to panic in the wake of Black Monday.
Pfizer
Pfizer (PFE) investor relations material
Pfizer Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 revenue was $16.583B, essentially flat year over year; non-COVID products grew 7% operationally and launched and acquired products grew 32%.
Reported diluted EPS was $0.56 and adjusted diluted EPS was $0.87; FY 2026 revenue and adjusted EPS guidance increased.
Management cited commercial execution, cost discipline and pipeline progress, with a risk-adjusted high-single-digit revenue CAGR aspiration from year-end 2028 through year-end 2033.
Financial highlights
Q3 net income attributable to common shareholders was $3.242B versus $3.541B; adjusted income was $4.985B versus $4.949B.
Adjusted gross margin was 77% and adjusted operating margin was 36%; the latter reflected the Innovent acquired IPR&D charge.
Adjusted SI&A was $3.2B, up 2% operationally, and adjusted R&D was $2.9B, up 18%, reflecting increased oncology and obesity investment.
Nine-month revenue rose 2% to $46.067B; reported net income was $5.681B versus $9.419B, and adjusted diluted EPS was $2.39 versus $2.56.
Nine-month earnings included $4.325B in intangible-asset impairments, including $3.8B for sigvotatug vedotin and $525M for Oxbryta.
Outlook and guidance
FY 2026 revenue guidance increased by $1.5B at the midpoint to $62.0B–$64.0B; adjusted diluted EPS guidance rose to $2.95–$3.05 from $2.80–$3.00.
Guidance includes adjusted SI&A of $12.5B–$13.5B, adjusted R&D of $10.8B–$11.8B and an adjusted effective tax rate of ~15.0%.
The outlook includes a $650M Innovent acquired IPR&D charge, with an adjusted EPS impact of ~$0.10, and an expected $1.1B unfavorable impact from generic and biosimilar competition; no 2026 share repurchases are assumed.
COVID product revenue expectation remains ~$4B; most Comirnaty revenue is expected in Q4, while Paxlovid utilization depends on infection rates and treatment demand.
Management expects a strong cadence of pipeline milestones; MEVPRO-1 readout is expected in Q1 2027 and MEVPRO-2 in Q4 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pfizer
- Vaccine-led Q1 growth lifted 2021 guidance while core-business growth remained on track.PFE
Q1 2021 - Vaccine-led growth lifted FY guidance as major pipeline programs advanced.PFEQ2 2021
- Record 2021 growth underpins $100B midpoint revenue guidance for 2022.PFEQ4 2021
- Comirnaty lifted Q3 growth and guidance as pipeline and safety risks persisted.PFEQ3 2021
- Adjusted EPS rose 44% as guidance improved, with pipeline and deals aimed at offsetting future LOEs.PFEQ3 2022
- COVID products drove 82% operational revenue growth; FY22 revenue outlook held at $98B-$102B.PFEQ1 2022
- Strong Q2 growth lifted FY22 operational guidance despite FX pressure.PFEQ2 2022
- Q4 growth and a deep launch pipeline underpin 2023 growth ex-COVID despite lower total revenue.PFEQ4 2022
- Non-COVID growth and a busy H2 launch slate underpin reaffirmed 2023 guidance.PFEQ1 2023
- COVID-19 declines drove Q2 revenue down 53%; FY Adjusted EPS guidance held at $3.25-$3.45.PFEQ2 2023
Next Pfizer earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
Pfizer
Next Pfizer earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
Related articles
)
Company research17 Jan 2024
The Largest Announced M&A Deals of 2023
Explore the biggest M&A deals of 2023, including major moves in energy, tech, and biotech sectors, reflecting a trend in strategic growth.
)
Company research26 Jun 2023
Class of 2013: A Journey Through the IPO Landscape of 2013
The year 2013 was a pivotal period in the world of business and finance. The global economy was recovering from the 2008 financial crisis, and companies were eager to capitalize on the renewed investor confidence. Among these were several game-changers and industry disruptors that chose 2013 to make their mark on the stock market
Frequently asked questions
A Pharmaceutical Powerhouse
Pfizer is a global pharmaceutical corporation headquartered in New York City. Founded in 1849, it is one of the largest pharmaceutical companies in the world. The company is known for the development and distribution of healthcare solutions across a broad range of therapeutic areas. Pfizer's portfolio includes medicines, vaccines, and consumer health products aimed at improving patient health and well-being.
From Chemicals to Combatting Covid
Founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, Pfizer began as a manufacturer of fine chemicals. The company expanded over the decades, becoming a multinational corporation that now stands as one of the world's largest pharmaceutical companies. It has introduced a number of notable drugs to the market, including Lipitor, Viagra, and Zoloft. In 2020, in response to the global COVID-19 pandemic, Pfizer collaborated with BioNTech and developed a vaccine that became one of the first to receive emergency use authorization worldwide.
From Serious Conditions to Minor Issues
Pfizer's product portfolio encompasses a wide range of medical needs, from treating serious illnesses to addressing minor health conditions. For life-threatening diseases such as cancer, Pfizer offers oncology drugs designed to improve survival rates and quality of life. On the other end of the spectrum, the company also provides over-the-counter consumer healthcare products for everyday ailments like pain, colds, and digestive issues.
Serving Patients Worldwide
Like many other pharmaceutical companies, with Eli Lilly being a good example, Pfizer's operations are widespread, extending to more than 125 countries across the globe. The company maintains a robust distribution network that ensures a wide reach for its products. Its global operations encompass research and development, manufacturing, marketing, and distribution of a broad range of pharmaceuticals and health solutions. This means that patients located in different countries have access to more or less the same offerings of medications, local regulations permitting.